133 related articles for article (PubMed ID: 31608242)
1. Corrigendum: Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway.
Cao H; Li W; Zhou Y; Tan R; Yang Y; Zhou Y; Guo Q; Zhao L
Front Oncol; 2019; 9():990. PubMed ID: 31608242
[TBL] [Abstract][Full Text] [Related]
2. Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway.
Cao H; Li W; Zhou Y; Tan R; Yang Y; Zhou Y; Guo Q; Zhao L
Front Oncol; 2019; 9():188. PubMed ID: 31024831
[TBL] [Abstract][Full Text] [Related]
3. Retraction: Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway.
Frontiers Editorial Office
Front Oncol; 2020; 10():714. PubMed ID: 32373542
[TBL] [Abstract][Full Text] [Related]
4. Oroxylin A reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12/CXCR7 axis in bone marrow microenvironment.
Li W; Ding Q; Ding Y; Lu L; Wang X; Zhang Y; Zhang X; Guo Q; Zhao L
Mol Carcinog; 2017 Mar; 56(3):863-876. PubMed ID: 27533597
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway.
Li X; Miao H; Zhang Y; Li W; Li Z; Zhou Y; Zhao L; Guo Q
Arch Toxicol; 2015 Jan; 89(1):121-36. PubMed ID: 24671465
[TBL] [Abstract][Full Text] [Related]
6. Wogonin reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12-CXCR4/7 axis in bone marrow microenvironment.
Cao H; Gao Y; Wang R; Guo Q; Hui H
Ann Transl Med; 2020 Sep; 8(17):1046. PubMed ID: 33145265
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia.
Liu P; Ma D; Yu Z; Zhe N; Ren M; Wang P; Yu M; Huang J; Fang Q; Wang J
Biomed Pharmacother; 2017 Jul; 91():21-30. PubMed ID: 28445830
[TBL] [Abstract][Full Text] [Related]
8. CXCL12/CXCR4 axis confers adriamycin resistance to human chronic myelogenous leukemia and oroxylin A improves the sensitivity of K562/ADM cells.
Wang Y; Miao H; Li W; Yao J; Sun Y; Li Z; Zhao L; Guo Q
Biochem Pharmacol; 2014 Aug; 90(3):212-25. PubMed ID: 24858801
[TBL] [Abstract][Full Text] [Related]
9. Oroxyloside A Overcomes Bone Marrow Microenvironment-Mediated Chronic Myelogenous Leukemia Resistance to Imatinib via Suppressing Hedgehog Pathway.
Zhang X; Liu Y; Lu L; Huang S; Ding Y; Zhang Y; Guo Q; Li Z; Zhao L
Front Pharmacol; 2017; 8():526. PubMed ID: 28848440
[TBL] [Abstract][Full Text] [Related]
10. CXCL12-CXCR4 contributes to the implication of bone marrow in cancer metastasis.
Shi J; Wei Y; Xia J; Wang S; Wu J; Chen F; Huang G; Chen J
Future Oncol; 2014 Apr; 10(5):749-59. PubMed ID: 24799056
[TBL] [Abstract][Full Text] [Related]
11. Expression of multidrug resistance 1 gene in association with CXCL12 in chronic myelogenous leukaemia.
Onishi I; Nakagawa Y; Murayama T; Hidaka M; Yamamoto K; Abe-Suzuki S; Abe S; Kurata M; Kitagawa M
Pathology; 2014 Dec; 46(7):623-9. PubMed ID: 25393253
[TBL] [Abstract][Full Text] [Related]
12. BM microenvironmental protection of CML cells from imatinib through Stat5/NF-κB signaling and reversal by Wogonin.
Xu X; Zhang X; Liu Y; Yang L; Huang S; Lu L; Wang S; Guo Q; Zhao L
Oncotarget; 2016 Apr; 7(17):24436-54. PubMed ID: 27027438
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of the CXCR4/CXCL12 axis blocks the activation of the Wnt/β-catenin pathway in human colon cancer cells.
Song ZY; Gao ZH; Chu JH; Han XZ; Qu XJ
Biomed Pharmacother; 2015 Apr; 71():46-52. PubMed ID: 25960214
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-kappaB and JNK/AP-1 pathways.
Scupoli MT; Donadelli M; Cioffi F; Rossi M; Perbellini O; Malpeli G; Corbioli S; Vinante F; Krampera M; Palmieri M; Scarpa A; Ariola C; Foà R; Pizzolo G
Haematologica; 2008 Apr; 93(4):524-32. PubMed ID: 18322253
[TBL] [Abstract][Full Text] [Related]
15. Corrigendum: Chloroquine Inhibits Stemness of Esophageal Squamous Cell Carcinoma Cells Through Targeting CXCR4-STAT3 Pathway.
Yue D; Zhang D; Shi X; Liu S; Li A; Wang D; Qin G; Ping Y; Qiao Y; Chen X; Wang F; Chen R; Zhao S; Wang L; Zhang Y
Front Oncol; 2022; 12():860158. PubMed ID: 35280817
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of CXCR4 Inhibits CXCL12-Induced Angiogenesis in HUVECs through Downregulation of the MAPK/ERK and PI3K/AKT and the Wnt/β-Catenin Pathways.
Song ZY; Wang F; Cui SX; Qu XJ
Cancer Invest; 2018 Jan; 36(1):10-18. PubMed ID: 29381400
[TBL] [Abstract][Full Text] [Related]
17. CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner.
Abdelouahab H; Zhang Y; Wittner M; Oishi S; Fujii N; Besancenot R; Plo I; Ribrag V; Solary E; Vainchenker W; Barosi G; Louache F
Oncotarget; 2017 Aug; 8(33):54082-54095. PubMed ID: 28903325
[TBL] [Abstract][Full Text] [Related]
18. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12.
Chinni SR; Sivalogan S; Dong Z; Filho JC; Deng X; Bonfil RD; Cher ML
Prostate; 2006 Jan; 66(1):32-48. PubMed ID: 16114056
[TBL] [Abstract][Full Text] [Related]
19. FZD7 regulates BMSCs-mediated protection of CML cells.
Liu N; Zang S; Liu Y; Wang Y; Li W; Liu Q; Ji M; Ma D; Ji C
Oncotarget; 2016 Feb; 7(5):6175-87. PubMed ID: 26716419
[TBL] [Abstract][Full Text] [Related]
20. Chemoattraction of bone marrow-derived stem cells towards human endometrial stromal cells is mediated by estradiol regulated CXCL12 and CXCR4 expression.
Wang X; Mamillapalli R; Mutlu L; Du H; Taylor HS
Stem Cell Res; 2015 Jul; 15(1):14-22. PubMed ID: 25957946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
